These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19031633)

  • 21. Managing bone parameters in dialysis patients: international guideline conflicts.
    Faull RJ
    Semin Dial; 2007; 20(3):191-4. PubMed ID: 17555479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Unawareness of the K/DOQI guidelines for bone and mineral metabolism in predialysis chronic kidney disease: results of the OSERCE Spanish multicenter-study survey].
    Bover J; Górriz JL; Martín de Francisco AL; Caravaca F; Barril G; Molinero LM;
    Nefrologia; 2008; 28(6):637-43. PubMed ID: 19016638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic kidney disease/bone and mineral metabolism: the imperfect storm.
    Williams ME
    Semin Nephrol; 2009 Mar; 29(2):97-104. PubMed ID: 19371800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [KDIGO guidelines for the diagnosis and treatment of chronic kidney disease mineral and bone disorder: what's new?].
    Limardo M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2010; 27(3):211-4. PubMed ID: 20540007
    [No Abstract]   [Full Text] [Related]  

  • 25. Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS.
    Tentori F
    Semin Dial; 2010; 23(1):10-4. PubMed ID: 20331811
    [No Abstract]   [Full Text] [Related]  

  • 26. [Principles and methodology of K/DOQI clinical guidelines].
    Tsukamoto Y
    Clin Calcium; 2004 May; 14(5):689-92. PubMed ID: 15577028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the new K/DOQI guidelines.
    Eknoyan G; Levin NW
    Blood Purif; 2002; 20(1):103-8. PubMed ID: 11803166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses.
    McCarley P
    Nephrol Nurs J; 2006; 33(4):423-6, 445; quiz 427-8. PubMed ID: 17002000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple factors affect renal dietitians' use of the NKF-K/DOQI Adult Nutrition Guidelines.
    Burrowes JD; Russell GB; Rocco MV
    J Ren Nutr; 2005 Oct; 15(4):407-26. PubMed ID: 16198933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction.
    Torregrosa JV; Bover J; Cannata Andía J
    Nefrologia; 2011; 31 Suppl 1():1-2. PubMed ID: 21468160
    [No Abstract]   [Full Text] [Related]  

  • 31. Forum of the End-Stage Renal Disease Networks' role in implementing the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines.
    Diamond LH; Daly DC
    Adv Ren Replace Ther; 1999 Jan; 6(1):28-35. PubMed ID: 9925147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of bone mineral content in patients with chronic renal failure.
    Gava A; Zorzetto M; Coghetto F; Teodori T; Marazzato G
    Rays; 1986; 11(3):67-70. PubMed ID: 3602467
    [No Abstract]   [Full Text] [Related]  

  • 33. Are the K/DOQI objectives for bone mineral alterations in stage 3-5 chronic kidney disease patients unreachable or inadequate?
    Fernández E
    Nefrologia; 2013 Jan; 33(1):1-6. PubMed ID: 23364622
    [No Abstract]   [Full Text] [Related]  

  • 34. Adherence to K/DOQI bone metabolism guidelines.
    Smith DH; Johnson ES; Thorp ML; Yang X
    J Ren Nutr; 2009 Jul; 19(4):334-42. PubMed ID: 19539186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DOQI guidelines/third in a series/Part II. Nutrition, pediatrics, patient selection. NKF-Dialysis Outcomes Quality Initiative.
    Nephrol News Issues; 1997 Aug; 11(8):54. PubMed ID: 9335785
    [No Abstract]   [Full Text] [Related]  

  • 36. Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease.
    Pendse S; Singh AK
    Med Clin North Am; 2005 May; 89(3):549-61. PubMed ID: 15755467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Conception and the control of CKD-MBD].
    Ookido I; Yokoyama K
    Nihon Jinzo Gakkai Shi; 2007; 49(4):433-7. PubMed ID: 17578189
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of patients in the implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative.
    Swartz MD; Robinson K; Davy T; Politoski G
    Adv Ren Replace Ther; 1999 Jan; 6(1):52-8. PubMed ID: 9925150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients.
    Noordzij M; Voormolen NM; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT; Korevaar JC;
    Nephrol Dial Transplant; 2009 May; 24(5):1580-7. PubMed ID: 19155531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How to apply and adapt international guidelines on bone metabolism and disease to the management of Japanese dialysis patients.
    Fukagawa M; Akizawa T
    Ther Apher Dial; 2005 Feb; 9(1):1-2. PubMed ID: 15828896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.